Biocon gets six-month extension on insulin supply pact

22 May 2025 , 12:42 PM

Biocon Limited announced that its subsidiary Biocon Biologics has received a six-months extension from the Malaysia government towards its insulin supply contract.

With this extension, the company’s Malaysian subsidiary, Biocon Sdn Bhd, will continue to supply recombinant human insulin products till October 2025.

The extension is part of an existing three-year pact signed in 2022 between Malaysia’s Ministry of Health (MoH), Biocon Sdn Bhd and Duopharma Marketing, as distribution partner.

The agreement was initially set to end in April 2025.

In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months. The extension shall be effective from April 29, 2025 to October 28, 2025.

Biocon Biologics operates a large-scale manufacturing facility in Johor and has been supplying insulin products to Malaysia for over a decade now. The company distributes these insulin products in Malaysia via its commercial partner DMKtg. The company has received the three-year contract earlier in April 2022.

The company also highlighted that the extension will be officially announced via a supplementary pact to be inked later by the Ministry of Health, DMktg, and Biocon.

At around 12.38 PM, Biocon was trading 2.16% lower at ₹333.30, against the previous close of ₹340.65 on NSE. The counter touched an intraday high and low of ₹340.60, and ₹332.60, respectively.

For feedback and suggestions, write to us at [e-mail]